Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes

NCT06820281 on ClinicalTrials.gov · last registry update 2026-09-16

A small phase 2 — 44 participants, against a typical 110. Due to report 31 December 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Whole-body insulin sensitivity. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: RECRUITING
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Victor Chang Cardiac Research Institute
Sponsor type: Other Gov
Enrollment: 44
Started: 2026-07-07
Primary completion: 2027-12-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Whole-body insulin sensitivity

Conditions studied

Type 1 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.